Liposomal formulation for treatment of visceral leishmaniasis

Abstract

Antigens from multiple sources is a promising strategy to effectively stimulate all immuno-phenotypic sections of a diverse population. Therefore, combination of multiple protective antigens is a rationale strategy to boost immunogenicity of the vaccine designed for immunization in heterogeneous population as well as to use in effective diagnosis in all endemic areas. The strategy to combine antigens isisis to construct a fusion chimeric multivalent antigen. The present invention relates to the diagnostic and vaccine potential of a recombinant multiantigenic T cell epitope enriched fusion protein comprising of three Leishmania donovani proteins, glycoprotein 63 (GP63), elongation factor 1 α (EF1-α) and cysteine protease C (CPC) against visceral leishmaniasis. The said invention in particular relates to designing, cloning and purification of a novel T cell enriched multiantigenic recombinant protein for detection of Leishmania infection in the form of antigen-specific antibodies in the biological samples such as serum and urine.

Dependencies are inferred from the claim text.